Digital twin of the human body may forecast health decline before it happens

NCT ID NCT07805044

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

Researchers are testing whether a computer model called a whole-body digital twin can predict how quickly a person bounces back after physical challenges like standing, walking, and thinking tasks. The study enrolls about 450 adults aged 18 to 80, including healthy people and those with stable heart, lung, or mobility conditions. Participants wear sensors and complete a standardized resilience test, with follow-up monitoring for up to 12 months. The goal is to see if the model accurately measures recovery across multiple body systems, which could one day help detect early signs of health decline.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A research-only whole-body digital twin built from wearable sensors, physical tests, and lab measures; no treatment is given.
What this could lead to
If the digital twin predicts recovery accurately, it could help doctors spot early signs of declining health or frailty before symptoms appear.
What could go wrong
This is an early observational study, not a treatment trial. The model may not prove accurate in real-world settings, and it is not designed to diagnose or guide care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Jun 2041

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will enroll approximately 450 community-dwelling adults aged 18 through 80 years from outpatient practices, research registries, community outreach, and digital recruitment channels. Approximately 150 participants will be enrolled in each of three cohorts: a Reference Health Cohort, a Stable Cardiometabolic Cohort, and a Stable Respiratory or Mobility Cohort. Recruitment will seek representation across age, sex, race, ethnicity, socioeconomic background, and functional status. Participants must be clinically stable and able to complete protocol assessments. Declining optional biospecimen collection will not preclude participation.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 through 80 years at enrollment. * Able and willing to provide written informed consent. * Able to understand study instructions and comply with protocol assessments. * Able to complete the standardized physiologic resilience challenge safely, with a customary assistive device or protocol-permitted accommodation when needed. * Clinically stable at screening, with no significant acute change in health status or prescribed medication regimen during the preceding 30 days, unless determined by the investigator not to affect participant safety or study measurements. * Willing to undergo multimodal physiologic monitoring and use study-provided or compatible wearable equipment. * Meets the criteria for one of the following prespecified cohorts: 1. Reference Health Cohort: Generally healthy adult without an unstable or clinically significant condition expected to prevent safe completion of the protocol or materially impair interpretation of the reference measurements. 2. Stable Cardiometabolic Cohort: Adult with one or more stable cardiometabolic conditions or risk factors, which may include controlled hypertension, dyslipidemia, obesity, prediabetes, or stable type 2 diabetes, without recent acute cardiometabolic decompensation. 3. Stable Respiratory or Mobility Cohort: Adult with a stable chronic respiratory condition or mobility-related functional limitation, without a recent exacerbation, acute injury, or acute functional decline that would make protocol assessments unsafe. * Participants meeting criteria for more than one clinical cohort will be assigned according to the prespecified cohort-classification hierarchy. * Participation in optional biospecimen collection requires separate consent; declining optional biospecimen collection will not otherwise exclude an eligible participant. Exclusion Criteria: * Inability or unwillingness to provide informed consent. * Acute illness, febrile illness, or suspected communicable infection at the time of assessment. * Hospitalization, major surgery, or clinically significant acute medical event within 30 days before enrollment, unless reviewed and cleared by the investigator. * Unstable cardiovascular disease, including recent acute coronary syndrome, decompensated heart failure, uncontrolled clinically significant arrhythmia, or symptomatic severe valvular disease. * Acute respiratory exacerbation, unstable oxygen requirement, or resting respiratory status that the investigator determines would make the challenge unsafe. * Resting blood pressure, heart rate, oxygen saturation, or other screening measurement outside the protocol-defined safety limits after repeat assessment. * Recent syncope, recurrent unexplained falls, acute musculoskeletal injury, or another condition that would prevent safe standing, walking, or recovery monitoring. * Neurologic, cognitive, psychiatric, visual, hearing, or communication impairment that would prevent informed consent or reliable completion of study procedures despite reasonable accommodation. * Known intolerance to required wearable sensors, electrodes, adhesives, or monitoring procedures that cannot be addressed using an approved alternative. * Participation in another clinical study or exposure to an investigational intervention that, in the investigator's judgment, could confound study measurements or increase risk. * Any medical, functional, or behavioral condition that the investigator or designated medical monitor determines would create an unacceptable risk or compromise the scientific validity of the collected data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiometabolic risk factors are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Mobility Limitation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Truway Health, Inc.

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.